Joshua Stolker, MD
Interventional Cardiology · Washington, MONPI 1447292875
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $940,208 of the $1,197,761 with a category attached, or 78.5%. 44 manufacturers reported payments, led by Novo Nordisk at 47.3% of the total. Among interventional cardiology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,387 payments — averaging $863.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$567K
- AstraZeneca$225K
- Boehringer Ingelheim$160K
- Lilly USA, LLC$156K
- Amgen$53K
- Bayer$14K
- plus $24K from 38 others
What the payments were for
- Consulting fees$176,94915%
- Speaking & faculty fees$940,20878%
- Travel & lodging$52,7724%
- Food & beverage$27,5012%
- Education$3320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$373,254
- JARDIANCE$309,309
- FARXIGA$122,780
- BRILINTA$79,720
- Repatha$50,768
- RYBELSUS$48,556
- Victoza$32,532
- Kerendia$13,736
- Tresiba$10,425
- PRALUENT$9,778
- Indigo System$1,422
- GUIDELINER$1,224
- SUPERA$950
- FLOWTRIEVER CATHETER, S$509
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$446
- AVVIGO Guidance System$425
- Impella$409
- Product in Development$300
- Diamondback Peripheral$285
- VERQUVO$249
How this compares
$1,197,761 in reported general payments places this provider in the 95th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 392 | $404,147 |
| XareltoRivaroxaban | 172 | $180,957 |
| JardianceEmpagliflozin | 132 | $138,199 |
| OzempicSemaglutide | 93 | $122,655 |
| Repatha SureclickEvolocumab | 132 | $115,091 |
| TrulicityDulaglutide | 23 | $45,157 |
| BrilintaTicagrelor | 42 | $38,696 |
| Praluent PenAlirocumab | 45 | $37,652 |
| FarxigaDapagliflozin Propanediol | 34 | $26,541 |
| EntrestoSacubitril/Valsartan | 18 | $24,350 |
| Varenicline Tartrate | 24 | $6,775 |
| Metoprolol Succinate | 497 | $5,660 |
| Rosuvastatin Calcium | 540 | $5,385 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 81 | $3,929 |
| Atorvastatin Calcium | 375 | $3,716 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $444 | $404,147392 claims |
| Johnson & JohnsonXarelto | $718 | $180,957172 claims |
| Boehringer IngelheimJardiance | $159,813 | $138,199132 claims |
| Novo NordiskOzempic | $566,899 | $122,65593 claims |
| AstraZenecaBrilinta, Farxiga | $224,952 | $65,23776 claims |
| Lilly USA, LLCTrulicity | $155,753 | $45,15723 claims |
| NovartisEntresto | $479 | $24,35018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 182 interventional cardiology providers in Missouri.
Other interventional cardiology in Washington
- Stephen KuehnWashington$57K
- John LasalaSaint Louis$936K
- Harvey SerotaSaint Louis$752K
- Jasvindar SinghSaint Louis$696K
- Gerald MancusoKansas City$402K
- James GranthamKansas City$357K
- Matthew BunteKansas City$242K
- Alan ZajariasSaint Louis$203K
- Anish ThomasSaint Louis$171K
- Gus TheodosSaint Louis$165K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.